Free Trial
NASDAQ:PODD

Insulet (PODD) Stock Price, News & Analysis

Insulet logo
$237.06 -14.75 (-5.86%)
Closing price 04:00 PM Eastern
Extended Trading
$238.48 +1.41 (+0.60%)
As of 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Insulet Stock (NASDAQ:PODD)

Key Stats

Today's Range
$230.05
$249.62
50-Day Range
$237.06
$288.29
52-Week Range
$160.19
$289.46
Volume
1.60 million shs
Average Volume
687,372 shs
Market Capitalization
$16.65 billion
P/E Ratio
40.94
Dividend Yield
N/A
Price Target
$292.06
Consensus Rating
Moderate Buy

Company Overview

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Remove Ads

Insulet Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
95th Percentile Overall Score

PODD MarketRank™: 

Insulet scored higher than 95% of companies evaluated by MarketBeat, and ranked 44th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Insulet has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Insulet has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Insulet's stock forecast and price target.
  • Earnings Growth

    Earnings for Insulet are expected to grow by 26.79% in the coming year, from $3.92 to $4.97 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Insulet is 40.94, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.50.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Insulet is 40.94, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.90.

  • Price to Earnings Growth Ratio

    Insulet has a PEG Ratio of 3.62. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Insulet has a P/B Ratio of 22.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Insulet's valuation and earnings.
  • Percentage of Shares Shorted

    3.09% of the float of Insulet has been sold short.
  • Short Interest Ratio / Days to Cover

    Insulet has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insulet has recently decreased by 11.48%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Insulet does not currently pay a dividend.

  • Dividend Growth

    Insulet does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.09% of the float of Insulet has been sold short.
  • Short Interest Ratio / Days to Cover

    Insulet has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Insulet has recently decreased by 11.48%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Insulet has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 27 news articles for Insulet this week, compared to 10 articles on an average week.
  • Search Interest

    Only 5 people have searched for PODD on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Insulet to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Insulet insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,722,512.00 in company stock.

  • Percentage Held by Insiders

    Only 0.47% of the stock of Insulet is held by insiders.

  • Read more about Insulet's insider trading history.
Receive PODD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Insulet and its competitors with MarketBeat's FREE daily newsletter.

PODD Stock News Headlines

Insulet Corp (PODD) Stock Price Down 4.67% on Mar 10
March 18th: Gold SHOCK?
On March 18th, an event is taking place that could completely shock the market. Stocks could go ballistic… Businesses could get blindsided… The gold market could get rocked… And one man, millionaire trader Jeff Clark is pounding the table on one single stock before this event. Because this one single stock has shown his readers gains of 85% in 14 days, 120% in under 3 months, and even 222% in just 8 days. While the past is no sure indicator for the future… Those gains could pale in comparison to what's coming.
Insulet (NASDAQ:PODD) Coverage Initiated at Royal Bank of Canada
Short Interest in Insulet Co. (NASDAQ:PODD) Declines By 11.5%
Insulet Corp (PODD) Trading Down 4.02% on Mar 7
See More Headlines

PODD Stock Analysis - Frequently Asked Questions

Insulet's stock was trading at $261.07 at the beginning of the year. Since then, PODD stock has decreased by 9.2% and is now trading at $237.06.
View the best growth stocks for 2025 here
.

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Thursday, February, 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.15. The medical instruments supplier earned $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. Insulet had a net margin of 20.19% and a trailing twelve-month return on equity of 24.46%.

Top institutional investors of Insulet include Vanguard Group Inc. (12.10%), Capital Research Global Investors (10.62%), Baillie Gifford & Co. (3.36%) and Geode Capital Management LLC (2.54%). Insiders that own company stock include Charles Alpuche, Timothy J Scannell, James Hollingshead, Wayde D Mcmillan, Bret Christensen, Mark N Field, Eric Benjamin, Michael P Spears, Lauren Budden, Dan Manea, Prem Singh, Shacey Petrovic and Luciana Borio.
View institutional ownership trends
.

Shares of PODD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Insulet investors own include Predictive Oncology (POAI), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Ford Motor (F), Bank of America (BAC), Wayfair (W) and Wells Fargo & Company (WFC).

Company Calendar

Last Earnings
2/20/2025
Today
3/10/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:PODD
Employees
3,000
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$292.06
High Stock Price Target
$355.00
Low Stock Price Target
$200.00
Potential Upside/Downside
+23.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
17 Analysts

Profitability

Trailing P/E Ratio
40.98
Forward P/E Ratio
60.53
P/E Growth
3.62
Net Income
$206.30 million
Pretax Margin
14.95%

Debt

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
$3.12 per share
Price / Cash Flow
75.96
Book Value
$10.49 per share
Price / Book
22.62

Miscellaneous

Free Float
69,815,000
Market Cap
$16.66 billion
Optionable
Optionable
Beta
1.29

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:PODD) was last updated on 3/10/2025 by MarketBeat.com Staff
From Our Partners